Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
63.08 USD   +0.80%
06/24Gilead Sciences Receives Positive CHMP Opinion for HIV Drug
06/24Gilead Sciences, Inc. - Treatment With Hepcludex (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
06/24Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

China Junshi's potential COVID drug shows promise in small trial

05/18/2022 | 01:00am EDT

BEIJING (Reuters) - An antiviral oral drug being co-developed by Shanghai Junshi Biosciences' subsidiary and other Chinese institutes showed early promise in speeding the clearing of virus in COVID-19 patients, according to a small clinical trial.

The drug, called VV116, is a derivative of Gilead Sciences Inc's COVID drug remdesivir and was approved for use in moderate to severe cases in Uzbekistan last year.

The viral shedding period, defined by its trial researchers as the duration between the first positive COVID test result and the first negative one, was 8.56 days for participants who took the experimental treatment within five days from the first positive test result.

That was shorter than 11.13 days seen in the control group, peer-reviewed data showed.

The trial involved 136 mild or moderate adult COVID infections recruited in March in China. Participants were given either the five-day course oral drug along with standard treatment or standard treatment only, researchers said in a paper published in the journal Emerging Microbes & Infections.

Overall, there was no significant difference between the viral shedding period for those who took VV116 more than five days after first positive result and the control group.

Limitations of the study include the small trial size and a higher portion of participants in the control group reporting symptoms, which could result in potential bias that researchers had to adjust with statistic model, the paper said.

The drug is undergoing a Phase III trial to evaluate its efficacy in mild to moderate patients in comparison with Pfizer Inc's oral pill Paxlovid, and a separate Phase III trial in moderate to severe cases.

China has approved Paxlovid as well as Brii Biosciences Ltd's antibody-based injection for mild and moderate COVID patients with high risk of progressing to severe conditions.

(Reporting by Roxanne Liu and Ryan Woo; Editing by Himani Sarkar)

ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BRII BIOSCIENCES LIMITED 1.75% 9.31 Delayed Quote.-72.16%
GILEAD SCIENCES, INC. 0.80% 63.08 Delayed Quote.-13.12%
PFIZER, INC. 2.99% 51.59 Delayed Quote.-12.63%
All news about GILEAD SCIENCES, INC.
06/24Gilead Sciences Receives Positive CHMP Opinion for HIV Drug
06/24Gilead Sciences, Inc. - Treatment With Hepcludex (Bulevirtide) Meets Primary Endpoint a..
06/24Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug R..
06/24Gilead Sciences, Inc. Announces Investigational Lenacapavir Receives Positive Chmp Opin..
06/24Gilead Gets CHMP Backing for Lenacapavir in Multi-Drug Resistant HIV
06/23Gilead Sciences Says Phase 3 Trial of Hepatitis Drug Meets Primary Endpoint
06/23Treatment With Hepcludex« (Bulevirtide) Meets Primary Endpoint and Achieves Significant..
06/23Gilead Sciences, Inc. Announces Week 48 Results from the Pivotal Phase 3 Clinical Trial..
06/23Gilead Reports Positive Results from Hepatitis Drug Trial
06/22Ex-girlfriend of biotech CFO pleads guilty to insider trading
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 24 543 M - -
Net income 2022 4 227 M - -
Net Debt 2022 16 327 M - -
P/E ratio 2022 17,9x
Yield 2022 4,60%
Capitalization 79 122 M 79 122 M -
EV / Sales 2022 3,89x
EV / Sales 2023 3,81x
Nbr of Employees 14 400
Free-Float 99,9%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 63,08 $
Average target price 69,65 $
Spread / Average Target 10,4%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-13.12%79 122
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574
GENMAB A/S-15.13%20 738